LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

Home・Akciju saraksts・Incyte Corp

Incyte Corp

Slēgts

SektorsVeselības aprūpe

103.18 2.37

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

100.6

Max

104.12

Galvenie mērījumi
By Trading Economics
Ienākumi	4.1M 303M
Pārdošana	-234M 1.3B
P/E Sektora vidējais	14.215 49.888
EPS	1.81
Peļņas marža	23.834
Darbinieki	2,844
EBITDA	-47M 368M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+6.93% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 28. jūl.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	1.1B 20B
Iepriekšējā atvēršanas cena	100.81
Iepriekšējā slēgšanas cena	103.18

Ziņu noskaņojums

By Acuity

32%

68%

81 / 344 Rangs Healthcare

Incyte Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 9. jūn. 23:49 UTC

Tirgus saruna

Nikkei May Fall Following Tech Stock Declines on Wall Street -- Market Talk

2026. g. 9. jūn. 23:45 UTC

Iegādes, apvienošanās, pārņemšana

Correct: Sigma Healthcare: Has Engaged in Preliminary Discussions in Boots Sale Process

2026. g. 9. jūn. 23:44 UTC

Iegādes, apvienošanās, pārņemšana

Sigma Healthcare Says No Certainty That Any Transaction Will Eventuate

2026. g. 9. jūn. 23:44 UTC

Iegādes, apvienošanās, pārņemšana

Sigma Healthcare: Continuously Reviews Opportunities to Create Value For Shareholders

2026. g. 9. jūn. 23:43 UTC

Iegādes, apvienošanās, pārņemšana

Sigma Healthcare: Has Engaged in Preliminary Discussions to Sell Boots

2026. g. 9. jūn. 23:35 UTC

Tirgus saruna

Oil Rises on Escalating Supply Disruption Concerns -- Market Talk

2026. g. 9. jūn. 22:06 UTC

Iegādes, apvienošanās, pārņemšana

Samsung: Element Has Expanded Rapidly Since 2022 Launch of AVITI

2026. g. 9. jūn. 22:05 UTC

Iegādes, apvienošanās, pārņemšana

Samsung: Element to Speed Commercialization of Gene-Sequencing Products

2026. g. 9. jūn. 22:05 UTC

Iegādes, apvienošanās, pārņemšana

Samsung: Additional Investment Makes It Largest Shareholder in Element

2026. g. 9. jūn. 22:05 UTC

Iegādes, apvienošanās, pārņemšana

Samsung Electronics Raises Stake in Element Biosciences With $175 Million Investment

2026. g. 9. jūn. 20:51 UTC

Peļņas

Micron, Marvell, Super Micro, Coherent, Smucker, and More Stocks That Explain Today's Market -- Barrons.com

2026. g. 9. jūn. 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 9. jūn. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 9. jūn. 20:09 UTC

Tirgus saruna

Cryptocurrency Traders Look for Bitcoin Bottom -- Market Talk

2026. g. 9. jūn. 19:36 UTC

Tirgus saruna

Cattle Climbs as Crude Oil Falls -- Market Talk

2026. g. 9. jūn. 19:32 UTC

Tirgus saruna

Barclays Oil Price Outlook Contingent on Hormuz Reopening -- Market Talk

2026. g. 9. jūn. 19:25 UTC

Tirgus saruna

U.S. Natural Gas Futures Slip in Rangebound Trade -- Market Talk

2026. g. 9. jūn. 19:00 UTC

Tirgus saruna

Oil Settles Lower on Continued Hopes for Middle East Deal -- Market Talk

2026. g. 9. jūn. 18:52 UTC

Iegādes, apvienošanās, pārņemšana

Warner Bros. Stock Hits a Low. Its Paramount Merger Return Is Getting Buzz. -- Barrons.com

2026. g. 9. jūn. 18:47 UTC

Tirgus saruna

No World Cup Inflation Seen So Far in Mexico -- Market Talk

2026. g. 9. jūn. 18:37 UTC

Tirgus saruna

Canada's Cooling Trade With the U.S. -- Market Talk

2026. g. 9. jūn. 18:27 UTC

Tirgus saruna

Precious Metals Lower as Trump Vows Military Response -- Market Talk

2026. g. 9. jūn. 17:35 UTC

Tirgus saruna

Treasury Yields, Dollar Briefly Rise on Trump's Iran Retaliation Threat -- Market Talk

2026. g. 9. jūn. 17:30 UTC

Tirgus saruna

Trump Post on Apache Helicopter Causes Brief Spike in Oil -- Market Talk

2026. g. 9. jūn. 16:34 UTC

Tirgus saruna

Cryptocurrency Weakness Follows Selling in Equities -- Market Talk

2026. g. 9. jūn. 16:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 9. jūn. 16:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 9. jūn. 16:20 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Health Care Roundup: Market Talk

2026. g. 9. jūn. 15:28 UTC

Tirgus saruna

Gold Futures Fall Further as Rate Fears Prevail -- Market Talk

2026. g. 9. jūn. 15:25 UTC

Tirgus saruna

Oil Extends Losses, Falling More Than 3.5% -- Market Talk

Salīdzinājums

Cenas izmaiņa

Incyte Corp Prognoze

Cenas mērķis

By TipRanks

6.93% augšup

Prognoze 12 mēnešiem

Vidējais 110.38 USD 6.93%

Augstākais 140 USD

Zemākais 75 USD

Pamatojoties uz 19 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Incyte Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

19 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 19 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Incyte Corp — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

81 / 344 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation